Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
奥拉帕尼治疗难治性异柠檬酸脱氢酶 1 (IDH1) 和 IDH2 突变型胆管癌:来自美国国家癌症研究所 10129 II 期试验的安全性和抗肿瘤活性
期刊:Cancer
影响因子:5.1
doi:10.1002/cncr.35755
Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das, Biswajit; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M